MX2023006077A - Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. - Google Patents

Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.

Info

Publication number
MX2023006077A
MX2023006077A MX2023006077A MX2023006077A MX2023006077A MX 2023006077 A MX2023006077 A MX 2023006077A MX 2023006077 A MX2023006077 A MX 2023006077A MX 2023006077 A MX2023006077 A MX 2023006077A MX 2023006077 A MX2023006077 A MX 2023006077A
Authority
MX
Mexico
Prior art keywords
aqueous
sustained release
suspension
release formulations
membrane emulsification
Prior art date
Application number
MX2023006077A
Other languages
English (en)
Inventor
Hunter Chen
Yiming Zhao
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023006077A publication Critical patent/MX2023006077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Se proporcionan métodos de emulsión de membrana no acuosa para producir micropartículas poliméricas y recubiertas de polímero. Algunas formas de modalidad proporcionan métodos para producir una micropartícula de liberación sostenida o controlada combinando proteína micronizada en polvo y un polímero en un disolvente de hidrocarburo para formar una primera solución no acuosa, agitando la primera solución no acuosa para formar una suspensión, alimentando la suspensión en una bomba de dispersión, en la que la suspensión se infunde a través de una membrana porosa en una fase continua que comprende un líquido de fluorocarbono y un fluorotensioactivo para formar una emulsión de hidrocarburo en fluorocarbono. Se eliminan el disolvente de hidrocarburo, el líquido de fluorocarbono y el fluorotensioactivo, y se recogen las micropartículas.
MX2023006077A 2020-11-25 2021-11-24 Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. MX2023006077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063118264P 2020-11-25 2020-11-25
PCT/US2021/060800 WO2022115588A1 (en) 2020-11-25 2021-11-24 Sustained release formulations using non-aqueous membrane emulsification

Publications (1)

Publication Number Publication Date
MX2023006077A true MX2023006077A (es) 2023-06-06

Family

ID=79021599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006077A MX2023006077A (es) 2020-11-25 2021-11-24 Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.

Country Status (11)

Country Link
US (1) US20220160828A1 (es)
EP (1) EP4251128A1 (es)
JP (1) JP2023551446A (es)
KR (1) KR20230113280A (es)
CN (1) CN116940347A (es)
AU (1) AU2021385363A1 (es)
CA (1) CA3191141A1 (es)
IL (1) IL303027A (es)
MX (1) MX2023006077A (es)
TW (1) TW202237070A (es)
WO (1) WO2022115588A1 (es)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AU2002322295C1 (en) 2001-06-21 2008-12-18 Altus Pharmaceuticals Inc. Spherical protein particles and methods of making and using them
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
EA034617B1 (ru) 2010-10-06 2020-02-27 Ридженерон Фармасьютикалз, Инк. Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r)
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
PT2780368T (pt) 2011-11-14 2018-03-22 Regeneron Pharma Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a
BR112014017882A2 (pt) 2012-01-23 2017-06-27 Regeneron Pharma formulações estabilizadas contendo anticorpos anti-ang-2
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
JP2017533695A (ja) 2014-09-16 2017-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗グルカゴン抗体およびその使用
EP3524352A1 (en) * 2014-10-24 2019-08-14 The Board of Trustees of the Leland Stanford Junior University Fluorinated pickering emulsion
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
WO2017075072A1 (en) * 2015-10-26 2017-05-04 University Of Wyoming Methods of generating microparticles and porous hydrogels using microfluidics
WO2017106716A1 (en) * 2015-12-16 2017-06-22 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
CN105878191B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用
US11634757B2 (en) * 2017-10-20 2023-04-25 Stilla Technologies Emulsions with improved stability
KR20220104797A (ko) * 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
AU2021401301A1 (en) * 2020-12-17 2023-08-03 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels

Also Published As

Publication number Publication date
IL303027A (en) 2023-07-01
CN116940347A (zh) 2023-10-24
JP2023551446A (ja) 2023-12-08
CA3191141A1 (en) 2022-06-02
AU2021385363A1 (en) 2023-06-08
TW202237070A (zh) 2022-10-01
KR20230113280A (ko) 2023-07-28
WO2022115588A1 (en) 2022-06-02
EP4251128A1 (en) 2023-10-04
US20220160828A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
Canelas et al. Dispersion polymerization of styrene in supercritical carbon dioxide: importance of effective surfactants
TW200842150A (en) Process for the preparation of an artificial latex
Thompson et al. Preparation of pickering emulsions and colloidosomes with relatively narrow size distributions by stirred cell membrane emulsification
Fujii et al. Stimulus-responsive particulate emulsifiers based on lightly cross-linked Poly (4-vinylpyridine)− silica nanocomposite microgels
Binks et al. Silica particle-stabilized emulsions of silicone oil and water: aspects of emulsification
Thompson et al. Covalently cross-linked colloidosomes
Bonham et al. Non-aqueous microgel particles: synthesis, properties and applications
Mawson et al. Stabilized polymer microparticles by precipitation with a compressed fluid antisolvent. 1. Poly (fluoro acrylates)
CN102617769A (zh) 一种纳米复合多孔凝胶微球及其制备方法
Niu et al. Anisotropic nanoparticles with controllable morphologies from non‐cross‐linked seeded emulsion polymerization
Sun et al. Preparation of uniform particle-stabilized emulsions using SPG membrane emulsification
Yan et al. CO2-responsive pickering emulsions stabilized by a bio-based rigid surfactant with nanosilica
Della Porta et al. Monodisperse biopolymer nanoparticles by continuous supercritical emulsion extraction
CN107141387A (zh) 一种可控自由基皮克林乳液聚合制备聚合物的方法
WO2014024971A1 (ja) マイクロカプセルの製造方法、及び、マイクロカプセル
Liu et al. Preparation of nanoparticles embedded microcapsules (NEMs) and their application in drug release
MX2023006077A (es) Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
CN105378026A (zh) 含电解质的水性聚合物溶液以及石油的三次采油的方法
CN105037603B (zh) 一种单分散共聚微球及其制备方法
Ong et al. Alginate‐based emulsion template containing high oil loading stabilized by nonionic surfactants
Dai et al. Golf ball-like particles fabricated by nonsolvent/solvent-induced phase separation method
CN102199242B (zh) 一种多孔高吸油性树脂的制备方法
CN103642053A (zh) 一种通过原位缩聚诱导大分子自组装制备颗粒乳化剂的方法
CN108355591A (zh) 聚二甲基硅氧烷引发乙基纤维素相分离制备微胶囊方法
Seiffert et al. Faster droplet production by delayed surfactant-addition in two-phase microfluidics to form thermo-sensitive microgels